Join Growin Stock Community!

Gelteq limited ordinary sharesGELS.US Overview

US StockHealthcare
(No presentation for GELS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GELS AI Insights

GELS Overall Performance

GELS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GELS Recent Performance

-1.72%

Gelteq limited ordinary shares

0.05%

Avg of Sector

-0.31%

S&P500

GELS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GELS Key Information

GELS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GELS Profile

Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.

Price of GELS

GELS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GELS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
19.62
PB Ratio
0.72
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
453252800.00%
Revenue Growth (YoY)
75.00%
Profit Growth (YoY)
75.00%
3-Year Revenue Growth
25.99%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
19.62
PB Ratio
0.72
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
453252800.00%
Revenue Growth (YoY)
75.00%
Profit Growth (YoY)
75.00%
3-Year Revenue Growth
25.99%
3-Year Profit Growth
25.99%

  • When is GELS's latest earnings report released?

    The most recent financial report for Gelteq limited ordinary shares (GELS) covers the period of 2024Q4 and was published on 2024/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GELS's short-term business performance and financial health. For the latest updates on GELS's earnings releases, visit this page regularly.

  • How much debt does GELS have?

    As of the end of the reporting period, Gelteq limited ordinary shares (GELS) had total debt of 3.9M, with a debt ratio of 0.19. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GELS have?

    At the end of the period, Gelteq limited ordinary shares (GELS) held Total Cash and Cash Equivalents of 3.05M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.